The Glucose Transporter 5 Enhances CAR-T Cell Metabolic Function and Anti-tumour Durability
Roddy S. O’Connor(University of Pennsylvania), Saar Gill(Parker Institute for Cancer Immunotherapy), Simon Heeke(The University of Texas MD Anderson Cancer Center), Andre Kelly(University of Pennsylvania), Feng Shen(University of Pennsylvania), Nicholas Jones(Swansea University), Nathaniel W. Snyder(Temple University), Adam Chatoff(Temple University), Alison Jaccard(Cancer Research Institute of the Slovak Academy of Sciences), John Scholler(University of Pennsylvania), Claudia V. Crispim(Temple University), Bakir Valentić(University of Pennsylvania), Alexander A. Shestov(University of Pennsylvania), Zhiyang Gan(University of Pennsylvania), Saba Ghassemi(Parker Institute for Cancer Immunotherapy)
Cited by 5
Related Papers
The Changing Epidemiology of Autism Spectrum Disorders
|Annual Review of Public Health|2017|1k
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|799
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554
Metabolic and epigenetic regulation of T-cell exhaustion
|Nature Metabolism|2020|443